- Home
- CLSK vs KNSA Comparison
CLSK vs KNSA Comparison
Compare CLSK & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- KNSA
- Stock Information
- Founded
- CLSK 1987
- KNSA 2015
- Country
- CLSK United States
- KNSA United Kingdom
- Employees
- CLSK N/A
- KNSA N/A
- Industry
- CLSK Finance: Consumer Services
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- CLSK Finance
- KNSA Health Care
- Exchange
- CLSK Nasdaq
- KNSA Nasdaq
- Market Cap
- CLSK 2.6B
- KNSA 2.6B
- IPO Year
- CLSK N/A
- KNSA 2018
- Fundamental
- Price
- CLSK $11.44
- KNSA $35.43
- Analyst Decision
- CLSK Strong Buy
- KNSA Strong Buy
- Analyst Count
- CLSK 9
- KNSA 6
- Target Price
- CLSK $20.66
- KNSA $40.83
- AVG Volume (30 Days)
- CLSK 18.8M
- KNSA 402.6K
- Earning Date
- CLSK 08-07-2025
- KNSA 10-28-2025
- Dividend Yield
- CLSK N/A
- KNSA N/A
- EPS Growth
- CLSK N/A
- KNSA N/A
- EPS
- CLSK 0.98
- KNSA 0.07
- Revenue
- CLSK $631,937,000.00
- KNSA $529,332,000.00
- Revenue This Year
- CLSK $111.14
- KNSA $37.21
- Revenue Next Year
- CLSK $46.10
- KNSA $11.99
- P/E Ratio
- CLSK $11.64
- KNSA $538.95
- Revenue Growth
- CLSK 84.66
- KNSA 56.18
- 52 Week Low
- CLSK $6.45
- KNSA $17.82
- 52 Week High
- CLSK $17.97
- KNSA $37.34
- Technical
- Relative Strength Index (RSI)
- CLSK 68.05
- KNSA 57.08
- Support Level
- CLSK $9.81
- KNSA $35.72
- Resistance Level
- CLSK $10.54
- KNSA $37.34
- Average True Range (ATR)
- CLSK 0.59
- KNSA 1.01
- MACD
- CLSK 0.27
- KNSA -0.12
- Stochastic Oscillator
- CLSK 91.58
- KNSA 53.31
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.